AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01084447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle training
Description: This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
Study NCT01084447 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
Study NCT03941730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03941730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03941730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT01554631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay ODT, BAYG5421)
Study NCT01554631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other ART regimens
Study NCT02601963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-103 1.5%
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Study NCT02601963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-103 3%
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Study NCT02601963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam (0%)
Description: The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
Study NCT00966160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir plus Lamivudine/Zidovudine
Description: 400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
Study NCT00966160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz plus Lamivudine/Zidovudine
Description: 600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
Study NCT02176824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy
Description: Sleep deprivation, Sleep phase advance, and Bright light therapy
Study NCT02176824 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.
Study NCT03526432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
Study NCT03941730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Estradiol
Description: Given PO
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: 25mg daily
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naloxegol
Description: 25mg daily
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: 30mg 4 times daily
Study NCT05249595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
Study NCT02176824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Codeine
Description: 30mg 4 times daily
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: codeine placebo
Description: 4 times daily (placebo will be made to match the codeine)
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine placebo
Description: 4 times daily (placebo will be made to match the codeine)
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naloxegol placebo
Description: placebo will match naloxegol, given daily
Study NCT02737059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxegol placebo
Description: placebo will match naloxegol, given daily
Study NCT04786925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: Control diet: A Mediterranean conventional diet based on the current dietary guidelines of the Spanish Society of Community Nutrition (SENC). Participants were strongly advised to use the Healthy Eating Plate (Harvard) to structure and prepare the main meals (lunch and dinner). In this way, at least ½ of the plate should be composed of vegetables, ¼ of lean protein, and ¼ of low glycemic index carbohydrates. The diet encourages participants to eat 5 times/day (breakfast, lunch, dinner, and two snacks). Overall, the control diet was based on high consumption of vegetables and fruits, whole grains, healthy fats (olive oil), and healthy proteins (legumes, fish, and lean meat). There was not energy restriction in the control diet.
Study NCT04786925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutriprecision diet
Description: Nutriprecision diet: a Mediterranean balanced diet based on the inclusion of precision foods designed according to the particularities of the senior population. The selected precision foods were a) fruit compote, b) smoothie, c) extruded meat product, d) wholemeal bread, e) wholemeal biscuit and f) microwaveable deep-frozen vegetable products. The diet encourages participants to eat 5 times/day with a conventionally balanced distribution of macronutrients (50% of the total caloric value from carbohydrates, 20% from proteins, and 30% from lipids). There was not energy restriction, although the energy requirements of the participants were adjusted to a BMI of 25 kg/m2 to avoid an overestimate of calorie intake. A mobile application designed and developed to provide volunteers with information about follow-up visits, the assigned diet, recommendations, and messages to motivate them during the intervention. A digital tool for cognitive stimulation.
Study NCT00810797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given orally
Study NCT00810797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: One year after completion of study treatment
Study NCT02446743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
Description: One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
Study NCT02446743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
Description: One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
Study NCT01966692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 1
Description: Fluticasone Propionate dry powder inhaler Formulation 1
Study NCT01966692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 2
Description: Fluticasone Propionate dry powder inhaler Formulation 2
Study NCT01966692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3
Description: Fluticasone Propionate dry powder inhaler Formulation 3
Study NCT01966692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Formulation 3*
Description: Fluticasone Propionate dry powder inhaler Formulation 3\*~\*(The asterisk) A different set of capsules from the same batch of formulation 3 is given to the subject to assess the within-subject variability and to ensure that the study is sufficiently powered to show bioequivalence between two replicates of the same formulation.
Study NCT04132180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
Study NCT01158118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Study NCT04132180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Mobilization
Description: The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
Study NCT04638504 — intervention group
Intervention type: OTHER
Intervention: ultrasonography
Description: vascular and adipose tissue measurement by ultrasonography
Study NCT01158118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Study NCT01166945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Study NCT01166945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Study NCT02825680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced NCP Support
Description: NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
Study NCT01166945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
Study NCT02825680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced NCP Support
Description: NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
Study NCT02825680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP
Description: The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model for Improvement, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool.
Study NCT00773149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (CAMPATH 1H) associated to G-CSF
Description: All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months.
Study NCT03351296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
Study NCT03351296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozocin
Description: streptozotocin 800 mg/m² day 1 every 14 days
Study NCT03351296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 750 mg/m² twice daily, days 1-14
Study NCT03167710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling, manipulation, stretching
Description: HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
Study NCT03167710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy, exercise, ultrasound
Description: Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
Study NCT02137356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard dose pelvic radiation therapy
Description: radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy
Study NCT02137356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard dose capecitabine
Description: 825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
Study NCT02137356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-escalated selinexor treatment
Description: Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
Study NCT01902303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual micro dosing of placebo for 7 days
Study NCT01902303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTL-TML-HSV
Description: Sublingual micro dosing of BTL-TML-HSV for 7 days
Study NCT02362932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sanitation
Description: Shared sanitation
Study NCT01699685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAB149
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study NCT01699685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAB149
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study NCT01699685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study NCT01699685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVA237
Description: Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
Study NCT01599676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline
Description: The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
Study NCT01599676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Non essential amino acid
Description: Non essential amino acid supplementation
Study NCT02821000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study NCT02255695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-based exercise program
Description: The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
Study NCT02415803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ticagrelor
Description: 90 mg loading dose, then 45 mg twice daily for 5 days
Study NCT02415803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional-dose ticagrelor
Description: 180 mg loading dose, then 90 mg twice daily for 5 days
Study NCT02415803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg loading dose, then 75 mg once daily for 5 days
Study NCT01142687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dihydrocapsiate capsule
Description: * Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
Study NCT01142687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dihydrocapsiate capsule
Description: * Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~* Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~* Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner
Study NCT04252118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: 3 times of MSCs(3.0\*10E7 MSCs intravenously at Day 0, Day 3, Day 6).
Study NCT04594083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palm Stimulator
Description: The Palm Stimulator, developed by the present researchers for the first time, is 1.6 cm in diameter, 4 cm in length, and has a cylindrical, non-slippery structure for an easy grip to ensure maximum contact with the palm The Palm Stimulator consists of blunt protrusions that will provide a tactile stimulus on the palm. The blunt protrusions do not penetrate into the skin. The simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
Study NCT04594083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker was placed in the ventrogluteal area properly 20 seconds before injection. It was fixed at the injection site until the injection process was completed.
Study NCT01389284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium ER (BAYH6689)
Description: 660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
Study NCT01389284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium IR (Aleve, BAYH6689)
Description: 220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
Study NCT01389284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium ER Placebo
Description: Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
Study NCT01389284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen Sodium ER Placebo
Description: Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
Study NCT01389284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium IR Placebo
Description: Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours